Surmodics (NASDAQ: SRDX) is one of 80 publicly-traded companies in the “Medical Equipment, Supplies & Distribution” industry, but how does it compare to its peers? We will compare Surmodics to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, valuation, risk, dividends and earnings.

Analyst Recommendations

This is a summary of current recommendations for Surmodics and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surmodics 0 0 2 0 3.00
Surmodics Competitors 215 1264 2728 96 2.63

Surmodics currently has a consensus target price of $40.00, suggesting a potential upside of 37.93%. As a group, “Medical Equipment, Supplies & Distribution” companies have a potential upside of 6.78%. Given Surmodics’ stronger consensus rating and higher possible upside, research analysts plainly believe Surmodics is more favorable than its peers.

Valuation and Earnings

This table compares Surmodics and its peers top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Surmodics $73.11 million $3.92 million 100.00
Surmodics Competitors $975.11 million $120.37 million 219.29

Surmodics’ peers have higher revenue and earnings than Surmodics. Surmodics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk & Volatility

Surmodics has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Surmodics’ peers have a beta of 1.06, indicating that their average share price is 6% more volatile than the S&P 500.


This table compares Surmodics and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Surmodics 5.37% 6.18% 5.11%
Surmodics Competitors -427.47% -43.41% -12.61%

Insider and Institutional Ownership

85.6% of Surmodics shares are owned by institutional investors. Comparatively, 65.7% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by institutional investors. 6.4% of Surmodics shares are owned by company insiders. Comparatively, 12.0% of shares of all “Medical Equipment, Supplies & Distribution” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Surmodics beats its peers on 7 of the 13 factors compared.

Surmodics Company Profile

Surmodics, Inc. is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device. The Company’s In Vitro Diagnostics segment manufactures or sells components for in vitro diagnostic immunoassay and molecular tests. The In Vitro Diagnostics segment manufactures and sells surface coatings to the diagnostic, biomedical research and life science markets. In Vitro Diagnostics segment offers protein stabilization reagents, substrates, antigens and surface coatings.

Receive News & Ratings for Surmodics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics and related companies with's FREE daily email newsletter.